Cargando…
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles
Alpha-synuclein (αS) is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). All diseases are determined by αS aggregate deposition but can be separated into...
Autores principales: | Meade, Richard M., Fairlie, David P., Mason, Jody M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647174/ https://www.ncbi.nlm.nih.gov/pubmed/31331359 http://dx.doi.org/10.1186/s13024-019-0329-1 |
Ejemplares similares
-
Peptide-based approaches to directly target alpha-synuclein in Parkinson’s disease
por: Allen, Scott G., et al.
Publicado: (2023) -
Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation
por: Torpey, James H., et al.
Publicado: (2020) -
Library-Derived Peptide Aggregation Modulators of
Parkinson’s Disease Early-Onset α-Synuclein Variants
por: Watt, Kathryn J. C., et al.
Publicado: (2022) -
Alpha-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease: The Emerging Role of VDAC
por: Risiglione, Pierpaolo, et al.
Publicado: (2021) -
Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)